BBlogFlow

Late rains bring bumper soybean crops for some southeastern Manitoba farmers - CBC

·7h ago

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

ManitobaA Springfield farmer's decision to plant less wheat in favour of crops like soybeans is paying off with a bumper crop. Fields are yielding up to 60 bushels per acreJura McIlraith · CBC News · Posted: Oct 22, 2026 6:00 AM EDT | Last Updated: 7 hours agoListen to this articleEstimated 3 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Manitoba farmer Andrew James decided to plant more soybeans this year, and that has paid off with a bumper crop. (Jura McIlraith/CBC)A Springfield farmer's decision to plant less wheat in favour of crops like soybeans is paying off with a bumper crop. Heavy rain, variable weather and high fuel costs created a worrisome season for Manitoba farmers, but things have worked out for some. For Andrew James, who farms in the rural municipality of Springfield east of Winnipeg, that's looking like average soybean yields of more than 60 bushels an acre. That is "absolutely exceptional," he said Friday. "As a farmer, I'm not budgeting those yields. I'm budgeting like 45. So, to get a bump like that is absolutely awesome.

This article is an excerpt. To read the full content, visit the original source. CBC

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

New $100-million auto parts manufacturer opens in Ingersoll - CTV News

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

CTV News·

L'Oreal says weight loss drugs are impacting beauty and skin care sales - BBC

The use of weight loss drugs, known as GLP-1s, has increased in popularity in recent yearsBeauty giant L'Oreal says the rise of weight loss drugs has affected beauty and skin care sales, as it designs products to specifically target some side effects of rapid weight loss. The company's head Nicolas Hieronimus said the beauty market was proving resilient in a challenging global context, and that the use of GLP-1s was "a very important phenomenon for us". He told an investor call that the rise in their use was "having an impact on beauty consumption and skin care consumption in particular". L'Oreal, which owns other popular brands including Maybelline and La Roche-Posay, announced on Thursday that sales in the three months to September rose by 7.7%, above analyst expectations. The use of GLP-1s has boomed in popularity in recent years, after drugs developed to treat diabetes such as Ozempic, Wegovy and Mounjaro were found to also lead to significant weight loss because they supress the appetite. While it is not caused by GLP-1 drugs directly, rapid weight loss can, for some people, come with a side effect of loose skin - including around the face.

BBC·

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% - Ars Technica

The tailored mRNA vaccine is intismeran (or mRNA-4157), which uses a synthetic mRNA that holds the unique genetic coding for up to 34 mutations in a patient’s own cancer cells. To produce the personalized vaccines, researchers compare the genetic sequences of a patient’s cancer cells with those of healthy cells and pick out cancer-specific mutations that could help the immune response selectively target just the cancer cells. In the trial, researchers assessed “recurrence-free survival” or RFS, which is the amount of time a patient has without the cancer returning, and “distant metastasis-free survival” or DMFS, which is the amount of time a patient has without the cancer returning and occurring in a different part of the body than where it began.

Ars Technica·